• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Long-term outcomes of upadacitinib in patients with prior dupilumab exposure: a case series.

作者信息

Gregoriou Stamatios, Koumprentziotis Ioannis-Alexios, Kleidona Ileana Afroditi, Bakakis Michail, Hatzidimitriou Eleni, Douvali Theodora, Tsiogka Aikaterini, Mastraftsi Styliani, Vaiopoulos Aristeidis, Stratigos Alexander

机构信息

1st Department of Dermatology and Venereology, Andreas Sygros Hospital, National and Kapodistrian University of Athens, Medical School of Athens, Athens, Greece.

出版信息

Arch Dermatol Res. 2025 Feb 12;317(1):387. doi: 10.1007/s00403-025-03918-4.

DOI:10.1007/s00403-025-03918-4
PMID:39937264
Abstract
摘要

相似文献

1
Long-term outcomes of upadacitinib in patients with prior dupilumab exposure: a case series.在先前接受度普利尤单抗治疗的患者中使用乌帕替尼的长期疗效：病例系列
Arch Dermatol Res. 2025 Feb 12;317(1):387. doi: 10.1007/s00403-025-03918-4.
2
Dupilumab-induced psoriasis in a patient with atopic dermatitis successfully treated with Upadacitinib: A case report.达必妥诱发特应性皮炎患者发生银屑病，使用乌帕替尼成功治疗：一例报告
SAGE Open Med Case Rep. 2025 Feb 3;13:2050313X251317811. doi: 10.1177/2050313X251317811. eCollection 2025.
3
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).从中度至重度特应性皮炎患者中切换使用度普利尤单抗转为乌帕替尼与继续使用乌帕替尼的疗效和安全性：3 期、随机、对照试验（Heads Up）的开放标签扩展研究结果。
J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23.
4
Refractory Dupilumab-Induced Inflammatory Arthritis Treated by Upadacitinib: A 'Janus Kinase (JAK)' of All Trades.乌帕替尼治疗难治性度普利尤单抗诱导的炎性关节炎：一种万能的“Janus激酶（JAK）”
Cureus. 2024 Sep 2;16(9):e68438. doi: 10.7759/cureus.68438. eCollection 2024 Sep.
5
Impact of Upadacitinib on Atopic Keratoconjunctivitis Exacerbated by Dupilumab Treatment in Atopic Dermatitis Patients: A Prospective Dermatological and Ophthalmological Clinical Evaluation in Common Clinical Practice.乌帕替尼对特应性皮炎患者中由度普利尤单抗治疗引发的特应性角结膜炎加重的影响：常见临床实践中的前瞻性皮肤病学和眼科临床评估
J Clin Med. 2024 Jun 28;13(13):3818. doi: 10.3390/jcm13133818.
6
Efficacy and Safety of Upadacitinib versus Dupilumab Treatment for Moderate-to-Severe Atopic Dermatitis in Four Body Regions: Analysis from the Heads Up Study.乌帕替尼与度普利尤单抗治疗四个身体部位中重度特应性皮炎的疗效和安全性：来自Heads Up研究的分析
Dermatology. 2025;241(1):10-18. doi: 10.1159/000542275. Epub 2024 Oct 30.
7
Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.比较度普利尤单抗暴露和初治患者应用乌帕替尼治疗特应性皮炎的长期疗效和安全性。
Clin Drug Investig. 2024 Jan;44(1):71-77. doi: 10.1007/s40261-023-01336-w. Epub 2023 Dec 17.
8
Efficacy, Safety, and Early Relapse After Cessation of Upadacitinib Versus Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis®: A Real-World Study in China.乌帕替尼对比度普利尤单抗治疗中重度特应性皮炎青少年患者停药后的疗效、安全性和早期复发：中国真实世界研究。
Dermatitis. 2024 Nov-Dec;35(6):636-645. doi: 10.1089/derm.2024.0014. Epub 2024 Aug 20.
9
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
10
Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up).乌帕替尼与度普利尤单抗治疗中重度特应性皮炎成人及青少年的疗效与安全性：一项开放标签、随机、疗效评估者设盲的头对头IIIb/IV期研究（升级研究）第16周结果
Br J Dermatol. 2024 Dec 23;192(1):36-45. doi: 10.1093/bjd/ljae404.

本文引用的文献

1
Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: Results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up).从中度至重度特应性皮炎患者中切换使用度普利尤单抗转为乌帕替尼与继续使用乌帕替尼的疗效和安全性：3 期、随机、对照试验（Heads Up）的开放标签扩展研究结果。
J Am Acad Dermatol. 2023 Sep;89(3):478-485. doi: 10.1016/j.jaad.2023.05.033. Epub 2023 May 23.
2
Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.度普利尤单抗治疗青少年及成人中重度特应性皮炎的真实世界疗效及耐受性。
Adv Ther. 2023 May;40(5):2509-2514. doi: 10.1007/s12325-023-02490-5. Epub 2023 Mar 21.
3
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
乌帕替尼治疗特应性皮炎患者的疗效，包括对度普利尤单抗和/或巴瑞替尼应答不足的患者：来自 BioDay 登记研究的结果。
Acta Derm Venereol. 2023 Feb 16;103:adv00872. doi: 10.2340/actadv.v103.5243.
4
Dupilumab nonresponders in atopic dermatitis.特应性皮炎中对度普利尤单抗无反应者。
Ann Allergy Asthma Immunol. 2022 Sep;129(3):267-268. doi: 10.1016/j.anai.2022.05.029.